Eli Lilly & Co. (LLY) call put ratio 1 call to 1.3 puts into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
February 5, 2026 12:35 PM ESTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,281.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "LLY already has a broad footprint in the obesity landscape - With what we believe to be the best drug incretin currently and an increasing uptake trend as indicated by scripts + strong data from Retatrutide + additional life cycle management strategies from LLY. We expect LLY to remain the market leader in the obesity space. We model WW peak Lilly revenues from obesity of 78B vs. $43B cons in year 2036E (our model terminal... More
